Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ChemGenex Pharmaceuticals |
---|---|
Information provided by: | ChemGenex Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00675350 |
PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
Condition | Intervention |
---|---|
Hematologic Tumors |
Drug: Omacetaxine |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | A Pharmacokinetic Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors |
Estimated Enrollment: | 12 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | February 2010 |
Estimated Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
This is an open-label non-randomized pharmacokinetic (PK) study of Homoharringtonine (Omacetaxine Mepesuccinate) administered as a subcutaneous (SC)injection to patients with relapsed and/or refractory hematologic malignancies and to patients with advanced solid tumors with no bone marrow involvement.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Be diagnosed with relapsed or refractory leukemia including chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS)
A non-fertile female is defined as:
Exclusion Criteria:
Contact: Ed Kirk | 650-421-8987 | ekirk@chemgenex.com |
Contact: Nisha Nanda | 650-421-8996 | nnanda@chemgenex.com |
United States, Texas | |
Mary Crowley Cancer Research Center | Recruiting |
Dallas, Texas, United States, 75201 | |
Contact: J.R. Doan 214-658-1943 jdoan@marycrowley.org | |
Principal Investigator: John Nemunaitis, M.D. |
Principal Investigator: | John Nemunaitis, M.D. | Mary Crowley Cancer Research Center |
Responsible Party: | ChemGenex Pharmaceuticals ( Ed Kirk ) |
Study ID Numbers: | CGX-635-205 |
Study First Received: | May 7, 2008 |
Last Updated: | May 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00675350 |
Health Authority: | United States: Food and Drug Administration |
Omacetaxine Homoharringtonine HHT Solid and hematologic malignant tumors |
Homoharringtonine Harringtonines |
Antineoplastic Agents Therapeutic Uses Growth Substances Physiological Effects of Drugs Growth Inhibitors |
Angiogenesis Modulating Agents Antineoplastic Agents, Phytogenic Angiogenesis Inhibitors Pharmacologic Actions |